Are There Head-to-Head Biologic Comparisons?

Severe refractory asthma, which affects approximately 1% to 5% of patients with asthma, is associated with increased morbidity and mortality. Author Juan Carlos Cardet, MD, MPH, of the University of South Florida joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the management of patients with severe refractory asthma, including first-line medications and biologics. Related Content:

• Management of Severe Refractory Asthma

-----------------------------------

JAMA Editors' Summary